Key result
Bivalirudin reduces ischemic and bleeding complications during PCI and is well tolerated when low-molecular-weight heparin is discontinued 8-14 hours before initiation.
Why the study?
Does bivalirudin reduce ischemic and bleeding complications in patients undergoing percutaneous coronary intervention?
Does bivalirudin reduce ischemic and bleeding complications in patients undergoing percutaneous coronary intervention?
Bivalirudin is an effective and well-tolerated anticoagulant for PCI that reduces both ischemic and bleeding complications without significant drug interactions.
Answers are grounded in this paper and cite their sources.
May guide anticoagulant choice in PCI after LMWH; leaves open confirmation in contemporary RCTs.
Much progress has been made in understanding and treating acute coronary syndromes. For patients undergoing percutaneous transluminal coronary angioplasty, anticoagulant therapy during the procedure must strike a balance between providing sufficient anticoagulation to prevent thrombus formation and ischemic complications while averting hemorrhagic complications. Bivalirudin, a thrombin-specific anticoagulant, is the only anticoagulant that reduces both ischemic and bleeding complications associated with percutaneous coronary intervention (PCI). Bivalirudin is easy to use, provides predictable anticoagulation, inactivates both free and clot-bound thrombin, and blocks thrombin-mediated platelet activation and aggregation. Drug-drug interaction studies have found no clinically relevant interactions between bivalirudin and ticlopidine, abciximab, tirofiban, or eptifibatide. Bivalirudin is well tolerated by patients who previously received low-molecular-weight heparin (LMWH), when LMWH is discontinued 8-14 hours before bivalirudin is started. Similarly, switching from heparin to bivalirudin at the time of PCI reduces both ischemic and bleeding events.
No takes yet. Share an insight, caveat, or question.
Reed et al. (2002) conducted a review in Acute coronary syndromes and percutaneous coronary intervention. Bivalirudin was evaluated. Bivalirudin reduces ischemic and bleeding complications during PCI and is well tolerated when low-molecular-weight heparin is discontinued 8-14 hours before initiation.
Synapse has enriched 10 related papers. Consider them for comparative context: